Navigation Links
Corgenix Medical Corp. Announces Launch of Products for Automated Systems
Date:3/2/2010

DENVER, March 2 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced the availability of its new automation friendly anti-phospholipid assay format.

The new format offers high-volume testing labs the same performance as the currently available Corgenix rapid assay with improved efficiency and high-volume analysis.

"Offering both extended and short assay formats allows us to maintain our leadership position in anti-phospholipid antibody detection," said Douglass Simpson, Corgenix CEO and President. "Our customers can now compete more effectively with enhanced automated performance."

Automated microplate ELISA processing from Corgenix is available for a wide range of anti-phospholipid antibody screening tests, including anti-Cardiolipin (aCL) antibodies, anti-Phosphatidylserine (aPS) antibodies and anti-Beta2 Glycoprotein I IgG antibodies.

As the first company to obtain FDA clearance of its anti-Cardiolipin test, Corgenix maintains its commitment to offer the highest quality tests associated with SLE (lupus) and antiphospholipid syndrome, autoimmune mediated thrombotic diseases. It is estimated that over 3 million individuals in the United States and 10 million worldwide have lupus or lupus-like disorders.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

SOURCE Corgenix Medical Corporation

Back to top

RELATED LINKS
http://www.corgenix.com

'/>"/>

SOURCE Corgenix Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Corgenix Reports Second Quarter Fiscal 2010 Financial Results
2. Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)
3. Corgenix Reports Financial Results for First Quarter of Fiscal 2010
4. Corgenix to Host Conference Call to Discuss Fiscal 2010 First Quarter Results
5. Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program
6. Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
7. International Merchant Advisors Reaches Agreement in Principal to Acquire First Medical Marijuana Clinic Operations
8. ATS Medical Announces Fourth Quarter and Full Year 2009 Results
9. First Perry Baromedical Sigma Elite Hyperbaric Chamber with EMR Installed at Stillwater Medical Center
10. Briggs Medical Service Company Receives ISO Registration and CE Mark Certification
11. APC Group, Inc. Reports Multi-Year Deal with Medical Device Manufacturer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/26/2016)... , April 26, 2016 Diplomat Pharmacy, ... of Jennifer Hagerman , Pharm D., to Vice ... growing role at Diplomat, Hagerman will continue to lead ... company that delivers custom education and training to Diplomat ... specialty pharmacy industry. Diplomat University also houses the quality ...
(Date:4/26/2016)... , April 26, 2016 Research ... and Credit Risk Analysis of the Biological Medicine Industry ... This comprehensive report analyzes the financial assessment and credit ... China . The report provides readers with an ... all market participants should be aware of. It considers ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... 2016 , ... One way to ignore solid evidence is to dismiss research ... toss the baby out with the bathwater when we ignore all studies because some ... and otherwise making better use of education policy research. , “When readers heed basic ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... USA Medical Card reminds us that May ... (CDC), a stroke is the fourth leading cause of death in the United States; someone ... almost a quarter of them in individuals under 65 years old. A stroke is ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... today announced a new Residency Education & Collaboration Platform for hospitals and ... resources, and a host of collaboration tools designed to improve patient outcomes ...
(Date:4/28/2016)... ... 2016 , ... A first-time look at workers’ compensation claims in Kentucky found ... Compensation Research Institute (WCRI) announced, and that costs per claim were stable between ... Edition , found that indemnity costs per claim and benefit delivery expenses per claim ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... has partnered with Community Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty ... of oncology by introducing an accreditation distinction. ACHC provides a wide range of ...
Breaking Medicine News(10 mins):